




Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs

Nalinie Joharatnam-Hogan^{1,8}  · Leo Alexandre^{2,3} · James Yarmolinsky⁴ · Blossom Lake⁵ · Nigel Capps⁵ · Richard M Martin^{6,7} · Alistair Ring⁸ · Fay Cafferty¹ · Ruth E Langley¹

Accepted: 11 January 2021 / Published online: 13 February 2021
© The Author(s) 2021

Abstract

Purpose of Review Repurposing established medicines for a new therapeutic indication potentially has important global and societal impact. The high costs and slow pace of new drug development have increased interest in more cost-effective repurposed drugs, particularly in the cancer arena. The conventional drug development pathway and evidence framework are not designed for drug repurposing and there is currently no consensus on establishing the evidence base before embarking on a large, resource intensive, potential practice changing phase III randomised controlled trial (RCT). Numerous observational studies have suggested a potential role for statins as a repurposed drug for cancer chemoprevention and therapy, and we review the strength of the cumulative evidence here.

Recent Findings In the setting of cancer, a potential repurposed drug, like statins, typically goes through a cyclical history, with initial use for several years in another disease setting, prior to epidemiological research identifying a possible chemo-protective effect. However, further information is required, including review of RCT data in the initial disease setting with exploration of cancer outcomes. Additionally, more contemporary methods should be considered, such as Mendelian randomization and pharmaco-epidemiological research with “target” trial design emulation using electronic health records. Pre-clinical and traditional observational data potentially support the role of statins in the treatment of cancer; however, randomised trial evidence is not supportive. Evaluation of contemporary methods provides little added support for the use of statin therapy in cancer.

Summary We provide complementary evidence of alternative study designs to enable a robust critical appraisal from a number of sources of the go/no-go decision for a prospective phase III RCT of statins in the treatment of cancer.

Keywords Drug repurposing · Statins · Cancer · Drug development

Abbreviations

CI	Confidence interval	HR	Hazard ratio
CLM	Cholesterol-lowering medication (CLM)	LDL	Low-density lipoprotein
CTT	Cholesterol Treatment Trialists	MR	Mendelian randomization
CVD	Cardiovascular disease	OR	Odds ratio
HMGCR	3-Hydroxy-3-methylglutaryl-coenzyme A reductase	RR	Relative risk
		RCT	Randomised controlled trial

This article is part of the Topical Collection on *Evolving Therapies*

✉ Nalinie Joharatnam-Hogan
n.j-hogan@ucl.ac.uk

¹ MRC Clinical Trials Unit at University College London, 90 High Holborn, London WC1V 6LJ, UK

² Norfolk and Norwich University Hospital NHS Trust, Norwich, UK

³ Norwich Medical School, University of East Anglia, Norwich, UK

⁴ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK

⁵ The Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK

⁶ Medical Research Council (MRC) Integrative Epidemiology Unit; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

⁷ National Institute for Health Research Bristol Biomedical Research Centre, Bristol, UK

⁸ Royal Marsden Hospital NHS Foundation Trust, Sutton, UK

Introduction

From a global cancer perspective, repurposing established medicines for a new clinical indication is potentially an important strategy, particularly due to the increasing cancer burden in low- and middle-income countries where access to costly new therapies and technologies is limited. A major advantage of assessing repurposing possibilities is that many of the early steps in the drug development pathway, i.e., phase I/II trials establishing safety and tolerability, are already completed and generic formulations

available. However, phase III randomised controlled trials (RCTs) are still needed to establish efficacy for the new clinical indication.

For new drugs, there is an established developmental pathway from pre-clinical evidence, through first in man studies, phase I and II trials leading to a phase III RCT (Fig. 1a). For repurposed drugs, the evidence base is different and there is no established consensus as to what this should comprise and how it should be appraised in order to prioritise potential repurposed drugs for phase III evaluation. Pre-clinical evidence can be complemented by




Fig. 1 a Standard drug development pathway⁹⁷. b Proposed drug development pathway for repurposed drugs

epidemiological data, previous randomised trials, and Mendelian randomization or more modern genetic studies.

Some would argue that any low-cost, established drug with minimal toxicity and some evidence of anti-tumour activity is a candidate for phase III evaluation particularly in tumour types with poor outcomes. Proponents of such an approach argue there is little to lose, as long as the trial participants are fully informed. However, a phase III trial particularly in the adjuvant setting is a costly, resource intensive, and long-term undertaking and the scientific rationale underpinning the trial needs to be robustly evaluated.

Statins, the most widely prescribed lipid-lowering agents, are inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) enzyme, the rate-limiting step in the mevalonate pathway (Fig. 2). Numerous large RCTs in a range of populations have confirmed the role of statins for the prevention and treatment of cardiovascular and cerebrovascular disease, and they have become well-established therapy in this setting [1–3]. Beyond their lipid-lowering action and cardiovascular benefits, evidence has suggested statins may have multiple pleiotropic actions, including anti-inflammatory, antioxidant, anti-proliferative, and immunomodulatory effects, potentially yielding clinically relevant anticancer properties [4].

The existence of extensive randomised data evaluating statins for cardiovascular disease (CVD) provides an opportunity to interrogate these data for evidence of clinical effects on cancer outcomes. A similar approach was taken for aspirin. Meta-analyses of individual patient data from large RCTs of


aspirin use in CVD prevention demonstrated significant reductions in cancer incidence, and risk of metastases [5]. These findings supported results from observational and pre-clinical data [6, 7]. Consequently, aspirin is now under investigation in several RCTs for the prevention of metastases [8].

Similarly, attention has turned to statins as a repurposed drug in the treatment of cancer. This review summarises the possible anticancer mechanism of action of statins and the breadth of evidence for and against its use in the prevention and treatment of cancer. Relative to previous reviews, a wider range of data sources and methods of evaluating the data is presented here, including the role of pharmaco-epidemiological research and Mendelian randomization to minimise potential confounding limiting the evaluation of observational studies [9]. We also present a novel model for assessing other drugs where there is potential for repurposing (Fig. 1b).

Potential Anticancer Mechanisms of Action of Statins

Inhibition of HMGCR leads to a decrease in mevalonate and downstream cholesterol biosynthesis, as well as the inhibition of other isoprenoid metabolites, required for a number of cellular functions and post-translational modification of cell signalling proteins [10] (Fig. 2). Several in vitro studies have demonstrated that statins act to inhibit a number of the

Fig. 2 The mevalonate pathway and possible mechanism of action of statins



hallmarks of cancer, including inhibition of angiogenesis, induction of apoptosis, repression of tumour metastases, and inhibition of tumour cell growth [11] (Fig. 2). Statins vary in their solubility, with hydrophilic statins more hepato-selective and lipophilic statins achieving a higher level of exposure in non-hepatic tissue [12]. Based on this classification, lipophilic statins, including simvastatin and atorvastatin, are considered to exert more pleiotropic effects and are, therefore, potentially more effective as anticancer therapies.

In vivo experiments have proven more conflicting. Early studies in animal models raised concerns that statins may have carcinogenic properties [11]. In rodent studies, administration of fluvastatin was shown to induce thyroid neoplasms and forestomach papillomas [13], lovastatin induced liver tumours [14], and administration of simvastatin led to follicular cell adenomas [15]. In studies demonstrating a procarcinogenic effect, the doses of statins used were far higher than the biologically relevant concentrations used to treat hypercholesterolaemia in humans, possibly explaining these detrimental effects. Although some animal models have demonstrated anticarcinogenic effects of statins [16], a review of all available rodent carcinogenicity data for lipid-lowering agents concluded that, on balance, both statins and fibrates promoted cancer in rodents even at the equivalent concentrations prescribed in humans [17].

Statins and the Prevention of Cancer—Observational Studies

A number of observational studies have supported the hypothesis of a protective effect of statins in terms of cancer risk [18–24]. One of the largest of these evaluated approximately 300,000 patients, using the Danish Cancer Registry, and found that any statin use reduced cancer incidence with an adjusted rate ratio (RR) for cancer overall of 0.86 (95% confidence interval (CI) 0.78 to 0.95) [25].

However, a number of other meta-analyses of observational studies of individual cancers have both disputed and supported a role for statins in the protection against cancer in equal measure [26–35]. One large meta-analysis including 25 observational studies and 17 randomised studies reviewed the effect of statins on all cancers, finding no effect on overall incidence (relative risk (RR) 0.96, 95% CI 0.72–1.2) [26]. However, a meta-analysis of 20 case-control studies suggested a significant beneficial association between statin use and risk of any cancer [35]. Although both large studies, these discrepancies reflect the inherent potential for bias, confounding, and heterogeneity between observational studies which could provide alternative explanations for any associations seen. An umbrella review and re-analysis of data from 43 meta-analyses, performed to determine the strength of the evidence available, found a statistically significant effect of statins on reducing cancer

incidence in 10 types of cancer when using traditional methods; however, when the evidence was graded, accounting for between-study heterogeneity and potential bias, it was not found to be “convincing” for any cancer type [36].

Statins and the Prevention of Cancer—Randomised Studies

A significant proportion of the evidence base underpinning the evaluation of aspirin as an anticancer drug originated from the long-term follow-up of large RCTs primarily designed to assess aspirin’s cardiovascular benefits [5, 37]. However, in similar randomised vascular trials of statin use, no difference has been shown in the incidence and risk of cancer. In the largest of these, the Heart Protection Study, 20,000 patients were randomised to 40 mg of simvastatin or placebo, with a reduction in cholesterol and proportional decrease in major vascular events seen in the statin cohort [38]. However, after a mean 11-year follow-up of survivors ($n = 17,519$), there was little evidence of a difference in the incidence of a first diagnosis of any cancer, either in-trial (first 5 years) or post-trial (subsequent 6 years) [39], or no difference by cholesterol level or tumour subtype.

In the early 2000s, a number of other RCTs assessing the effect of statins on the primary and secondary prevention of CVD consistently demonstrated vascular benefits. However, a large meta-analysis of 26 RCTs including 86,936 participants with 6662 incident cancers and 2407 cancer deaths showed that statins had a neutral effect on both incidence of cancer and cancer deaths, regardless of cancer subtype [40, 41]. To address specific concerns regarding the effect of lowering low-density lipoprotein (LDL) cholesterol with statins and potential risk of cancer, the Cholesterol Treatment Trialists’ (CTT) Collaboration performed a series of meta-analyses of individual patient data ($n = 174,149$) from 27 randomised vascular trials. They demonstrated that reducing LDL concentration with statins had no effect on either cancer incidence (RR per 1.0 mmol/L LDL reduction 1.00, 95% CI 0.96–1.04) or mortality (RR 0.99, 95% CI 0.93–1.06) [3, 42–44]. Statins were used for a median of 5 years, and no difference emerged regardless of whether trials were of statins versus control or trials of a more versus less intensive statin regime. Analyses of the effect of statins on individual cancers (23 different primary sites), by gender, older age, or statin type, were also consistent for a lack of association [45•]. These meta-analyses are probably the strongest available evidence to suggest that statins are unlikely to reduce the risk of incident cancer overall, at least in the short to medium term.

The implications for cancer-related mortality may be less clear. The included trials were for the primary and secondary prevention of CVD and the majority of patients enrolled would not be expected to have a cancer diagnosis at the time

of randomization. Indeed, only cancers diagnosed after randomization were considered (1.4% developed cancer per year after randomization in the CTT study [46]), and it is not clear how many and for how long patients received the study drug after diagnosis. Whilst detailed information on statin use after a cancer diagnosis is not available in this data, statins are not routinely discontinued during cancer therapy, and therefore, some effect on mortality might be expected if there was a therapeutic role. Detailed follow-up of the data would be useful to make a more informed inference about the effect of allocation to statins on mortality outcomes in patients with cancer from these meta-analyses.

The Role of Pharmaco-epidemiological Research

In contrast to the usual pathway for new drug development (phase I, II, and III trials), the rationale for a trial of a repurposed drug in the setting of cancer prevention or treatment can be informed by pharmaco-epidemiological research. In the past decade, there has been a marked proliferation in such research, due to a growing availability of population-based datasets drawn from a number of routinely collected health data sources (including electronic health records, pharmacy records, disease registries and outcome datasets) [47, 48]. Such research can leverage the availability of accurate prescription data in defined cohorts, with comprehensive data on relevant covariates and outcomes, to estimate the real-world effectiveness of statins in cancer prevention and treatment. There are notable examples where pharmaco-epidemiology has critically informed the justification for similar trials of other repurposed drugs in cancer prevention and treatment [8, 49]. Indeed, the AspECT trial, a 2×2 phase III trial of esomeprazole and aspirin for the prevention of a composite outcome of death, adenocarcinoma, and high-grade dysplasia in patients with Barrett's oesophagus, was justified in part on the available pharmaco-epidemiological evidence and, ultimately, yielded some evidence for a chemo-protective effect consistent with this research [49]. However, there are also well-known examples where observational studies conflict with randomised data [50]. A common explanation for such discrepancies is the propensity for observational research to be susceptible to residual confounding, due to an imbalance of prognostic factors between treatment groups not accounted for in analyses, brought about by a lack of random treatment assignment [51]. However, observational studies can differ from randomised trials in other important ways to explain such discrepancies, including their design and analysis, with residual confounding a lesser concern in some instances [52]. To minimise these flaws, observational study design requires the emulation of a pragmatic hypothetical target trial (a randomised trial that would answer the question of interest),

including explicit description of the causal framework, specifying the protocol of the target trial, robust reporting of study design, and a structured process for the analysis of study limitation [47, 53]. Use of such an approach in large healthcare datasets provides the opportunity to assess the association between a treatment and outcome using real-world data and helps to reduce the discrepancies between the effect estimates from observational studies and randomised trials [54••]. These are welcome steps towards improving the application of results from observational research, including, in this context, to improve their utility in informing the justification for or against a trial of adjuvant statin therapy.

An analysis of the electronic health records of 733,804 UK adults, explicitly emulating a target trial of statins and cancer, found little evidence to indicate that statin therapy influences cancer incidence after 10-year follow-up [54••], regardless of cancer subtype, and consistent with findings of the CTT Collaboration. The authors further demonstrated that the failure in replicating observational study results arose from the deviation from the basic principles of a trial design [54••]. Eligibility criteria included LDL cholesterol level $< 5 \text{ mmol L}^{-1}$, which may have introduced some confounding, channelling people with diabetes into the statin group (diabetes being an indication for statin therapy irrespective of LDL), and diabetes is a known risk factor for cancer. However, pharmaco-epidemiological research could be utilised much like this example to supplement the evidence base for a phase III repurposed drug trial, but perhaps also to provide more timely results to support clinical decision making.

The Role of Mendelian randomization

Conventional observational epidemiological studies are vulnerable to various biases (e.g., residual confounding, reverse causation, and measurement error) which undermine causal inference. Mendelian randomization (MR) uses genetic variants to proxy risk factors to generate more reliable evidence in support of causal effects of these factors on health outcomes in observational settings [9]. Since germline genetic variants are randomly assorted at meiosis and fixed at conception, MR analyses should be less prone to confounding than conventional observational studies (e.g., by indication, lifestyle factors) and are not subject to reverse causation bias. Further, measurement error in genetic studies is often low and MR estimates the life-long effects of risk factors on health outcomes, allowing sufficient time for diseases with long latency periods—like cancer—to develop an advantage over secondary analyses of short-term RCTs. MR relies on sound knowledge of the mechanism of action and existence of a relevant genetic variant, and therefore, it may not be possible or useful for all drug evaluations. However, findings from well-conducted and adequately powered MR studies, with

appropriate sensitivity analyses to evaluate the assumptions of MR [55], could provide a useful contribution to the evidence synthesis of statins as a potential preventive agent or therapeutic treatment for cancer.

A commonly employed approach for inferring causal effects of statins on cancer in an MR context is to utilise genetic variants in the gene encoding the drug target of statins, *HMGCR*, that are robustly associated with LDL cholesterol levels as proxies for pharmacological inhibition of this drug target. One such study employed the LDL cholesterol-lowering T-allele of rs12916 (located within *HMGCR*) as a proxy for HMG-CoA reductase inhibition to examine the effects of its inhibition on risk of cancer in the Malmö Diet and Cancer Study [56]. The authors reported little evidence for an effect of *HMGCR* inhibition on overall cancer risk (HR equivalent to 0.07 mmol/L lowering of LDL cholesterol 0.99, 95% CI 0.95–1.02), though statistical power was modest for this analysis ($n = 6528$ cases). In an analysis of 22,773 men with prostate cancer and 23,050 controls in the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium, a weak protective effect was reported of the rs12916-T variant with prostate cancer risk (OR 0.97, 95% CI 0.94–1.00; $p = 0.03$) [57], and little evidence apparent of an association with stage or tumour grade. Three variants in *HMGCR* were evaluated in relation to risk of breast cancer in 122,977 cases and 105,974 controls in the Breast Cancer Association Consortium (BCAC) [58]. Similarly weak evidence was demonstrated for a protective effect of *HMGCR* inhibition on cancer risk (OR equivalent to 1 mmol/L lowering of LDL cholesterol 0.86, 95% CI 0.73–1.02, $p = 0.09$) [58], with comparable odds when analyses were restricted to status of oestrogen receptor. Most recently, a study of genetically proxied *HMGCR* inhibition, equivalent to a 1-mmol/L reduction in LDL cholesterol, demonstrated robust evidence of a lower risk of epithelial ovarian cancer (OR 0.60, 95% CI 0.43–0.83; $p = 0.002$) in both the general population and in BRCA 1/2 mutation carriers (HR 0.69, 95% CI 0.51–0.93; $p = 0.01$) [59], consistent with pre-clinical and epidemiological studies, perhaps warranting further investigation in this high-risk group. Going forward, the integration of MR with other complementary genetic approaches may provide a promising opportunity for validating the effects of drug targets like *HMGCR* on cancer outcomes. For example, Zheng et al. have reported that combining evidence from MR and colocalization analysis, a technique that helps to distinguish shared causal variants across traits from genetic confounding due to linkage disequilibrium, can substantially increase the likelihood of predicting positive clinical trial outcomes leading to regulatory approval of new drugs [60].

Extension of the MR approach to various other cancers within the context of adequately powered datasets along with

the application of this approach to the study of cancer progression or recurrence [61], rather than cancer incidence, remains a fruitful area of investigation. The latter is important as the utility of a particular agent in the context of risk reduction (primary prevention) may not necessarily translate to a therapeutic effect in the context of disease progression (tertiary prevention), and vice versa. Insights gained from the use of MR in interrogating causal relationships between statin use, cancer occurrence, and cancer outcomes can therefore provide complementary evidence to other study designs on the potential role of long-term statin therapy in reducing incidence or progression of cancer.

Table 1 summarises the types of evidence evaluating statin therapy in the prevention of cancer.

Statins and the Adjuvant Treatment of Cancer

Evaluating “Traditional” Evidence for Statins in the Treatment of Cancer

A possible role for statins in the adjuvant setting of cancer has been suggested by a recent *in vitro* study, where statins were shown to reduce the outgrowth of metastases in two breast cancer cell lines [62]. It has therefore been suggested that statins could delay breast cancer recurrence and reduce mortality [63]. A number of population-based cohort studies have demonstrated that statins may reduce cancer-specific mortality in breast, colorectal, and lung cancer [64–66]. One of the largest of these reviewed statin use in Danish residents diagnosed with stage I–III invasive breast cancer ($n = 18,769$). Simvastatin users developed approximately 10 fewer breast cancer recurrences per 100 women after 10 years, with 10-year adjusted HR 0.70 (95% CI 0.57–0.86) [67, 68]. In a meta-analysis of 10 observational studies, including 32,373 patients with breast cancer, lipophilic statin use was shown to be associated with improved recurrence-free survival (HR 0.64, 95% CI 0.53–0.79) at 5-year follow-up [69]. However, many of these studies are affected by collider stratification bias—unmeasured confounding induced by selected bias—and an evaluation of alternative explanations is crucial [70].

The potential survival benefit of statins for patients with malignancy has been further evaluated in a meta-analysis of 95 cohort studies, including 1,111,407 individuals. Subgroup analyses according to initiation of statins showed that post-diagnosis statin use was associated with a significant improvement in recurrence-free survival (HR 0.65; 95% CI 0.54–0.79), which was less convincing for pre-diagnosis use (HR 0.86, 95% CI 0.77–0.96); a similar association was seen for overall survival (OS) [71]. Most studies identified were in prostate, breast, and colon cancer, with consistent benefits

Table 1 A summary of the different type’s evidence for statins in the chemoprevention of cancer, with examples

Type of evidence	Study	Number of studies/cases	Results (95% confidence interval)
In vivo evidence at biologically relevant doses	Newman, JAMA [17] (1996)	Review of rodent carcinogenicity studies	Statins increase incidence of cancer
Statins and cancer prevention	Kuoppala, Eur J Cancer [26] (2008)	42 differing study designs	RR 0.96 (0.72–1.12)
Meta-analyses of epidemiological data	Taylor, Eur J Cancer Prevention [35] (2008)	n=67,432 cases 20 case-control n=100,129 26 RCT n=6662 cases	OR 0.71 (0.56–0.89)
Meta-analyses of RCTs	Dale, JAMA [40] (2006)	21 RCT	OR 1.02 (0.97–1.07)
Individual patient data from RCTs	Kim, Indian J Cancer [41] (2017)	n=32,615 on statin 27 RCT n=175,000	RR 0.97 (0.92–1.02)
Pharmaco-epidemiology using a target trial design	CTT, Lancet [42] (2012), PLOS [46] (2012), Lancet [44] (2010), Lancet [45*] (2019) Dickerman, Nature Medicine [54••] (2019)	n=28,408 cases	Incidence RR 1.00 (0.96–1.05) Mortality RR 1.00 (0.93–1.08) Cancer-free survival difference –0.5% (–1.0%–0.0%)
Mendelian randomization	Orho-Melander, Int J Epidemiol [55] (2018)	n=6528	HR equivalent to 0.07 mmol/L LDL lowering 0.99 (0.95–1.02)
	Bull, Cancer Medicine [56] (2016)	n=22,773 prostate	OR 0.97 (0.94–1.00)
	Nowak, Nature communications [57] (2018)	n=122,977 breast	OR equivalent to 1 mmol/L LDL lowering 0.86 (0.73–1.02)
	Yarmolinsky, JAMA [58] (2020)	n=25,509 ovarian n=3887 BRCA 1/2	OR 0.6 (0.43–0.83) OR 0.69 (0.51–0.93)

seen across these three tumour types. However, a recent umbrella review of meta-analyses, an appraisal of high-level evidence, evaluating data from 112 meta-analyses of observational studies and 144 meta-analyses of RCTs, found only class III (suggestive) evidence of decreased cancer-related mortality in patients with cancer who had statins post-diagnosis, concluding limited convincing evidence of an effect of statins on cancer mortality in the adjuvant setting [72].

The evidence for the use of statins post diagnosis of cancer appears most abundant in the setting of breast cancer [69, 73, 74]. However, as with other tumour types, most data exists in the observational setting, with little randomised evidence. The Breast International Group's large RCT (BIG 1-98) appears to be the only observational study of statin use in the adjuvant setting of breast cancer in the context of a randomised controlled trial of endocrine therapy. Survival of 8010 postmenopausal women with early-stage, hormone receptor-positive breast cancer was assessed, in whom 789 initiated cholesterol-lowering medication (CLM) during endocrine therapy [75]. In patients commenced on CLM (including non-statins), an association with improved disease-free survival (HR 0.79; 95% CI 0.66 to 0.95), breast cancer-free interval (HR 0.76; 95% CI 0.60 to 0.97), and distant recurrence-free interval (HR 0.74; 95% CI 0.56 to 0.97) was demonstrated [75].

Pharmaco-epidemiological Research in the Adjuvant Setting of Cancer

The majority of observational research examining the association between statin use and survival after a diagnosis of cancer compares outcomes between current users (including prevalent users) and never users. This answers a fundamentally different question to that posed by RCTs: whether allocation to statins (new users) compared with no statins at the point of randomization affects survival. There have been considerable methodological advancements to improve consistency of estimates from observational research with trials, including *new-user designs* (which restricts analysis to individuals under observation at the start of the treatment of interest) [76] and their incorporation into a wider paradigm shift: emulation of a target trial using observational datasets [53]. The latter requires the explicit alignment of the protocol for an observational study to that of the hypothetical "target" trial (described previously), specifically with regard to the eligibility criteria, treatment strategies, assignment procedures, outcome, causal contrasts of interest (intention to treat and per-protocol effects), and analysis plan [53]. To date, a single study has employed such an observational analogue of a target trial in this context—a retrospective analysis of US SEER (Surveillance, Epidemiology, and End Results) data from 17,372 patients. This study found that initiation of statins within 6 months after cancer diagnosis (stages I–III colorectal,

breast, prostate, and bladder) did not improve 3-year cancer-specific or overall survival [77]. This approach accounted for potential selection and immortal time bias, and the effect of residual confounding was likely to be negligible (HR for OS 1.00, 95% CI 0.88–1.15), although longer-term follow-up is important. The application of this methodology to other cancer types would be welcome in informing the decision to proceed to a trial.

Evidence from Mendelian randomization

There is now a large body of evidence using MR to evaluate the effect of genetic risk on cancer incidence, with a number specifically evaluating HMGCR inhibition. However, few studies have attempted to identify variants associated with cancer progression, and those that have are mostly small [61, 78]. A number of issues have been identified in Mendelian randomization of progression⁶¹. Compared to cancer incidence, which is usually a binary outcome, disease progression is more complex to measure and harder to define. There is an increased potential for confounding through collider bias, leading to a possible spurious association between the genetic variant and progression. Furthermore, MR requires availability of large data sets with detailed follow-up of both progression and genetic data [61]. Therefore, for a MR study of progression to be successful, large, and likely collaborative, RCTs collecting DNA as a standard are required. To date, few studies have used MR to identify factors influencing disease progression [78–80], and to our knowledge, none evaluating HMGCR inhibition as a proxy for statin therapy.

Randomised Trials Investigating Statins in Cancer

Most randomised trials investigating statins in cancer have been in advanced cancers, with few in the adjuvant setting, and most-earlier phase (non-confirmatory) studies with relatively small sample sizes (Table 2).

Any favourable effects of statins on cancer-related mortality apparent from epidemiological data have not always been corroborated by clinical trials, and the trial evidence demonstrated in Table 2 has not all been sufficiently robust to confirm or refute the effectiveness of statins in cancer. In Kawata et al.'s phase II study of advanced hepatocellular cancer, patients received treatment with transcatheter arterial embolisation and 5-fluorouracil chemotherapy and were randomised to 40 mg of pravastatin or control, with a doubling of median OS seen from 9 to 18 months ($p = 0.006$) [81]. This study had a sample size of only 83 patients; and the findings were subsequently not replicated in the PRODIGE-11 trial, an RCT of 323 patients with advanced hepatocellular carcinoma randomised to first line sorafenib-pravastatin (40 mg)

Table 2 Randomised trials investigating statins in patients with cancer

Study	Phase	Cancer	Previous treatment	Statin	Standard treatment	No. of patients	Median OS (months) and HR statin vs placebo
Kawata 2001, BJC [81]	II	Advanced liver	No	Pravastatin 40 mg	TAE, F/u	83	18 vs 9 m HR 0.50, <i>p</i> =0.006
Garwood 2010, BCRT [82]	II	DCIS or stage I breast	No	Fluvastatin 20 vs 80 mg	Statin 3–6 weeks before surgery	40	Ki67 reduced, CC3 increased
Kim 2014, EJC [83]	III	Advanced gastric	No	Simvastatin 40 mg	Capecitabine and cisplatin	244	11.6 vs 11.5 m, HR 0.97, <i>p</i> =0.82
Hong 2014, CCP [84]	II	Advanced pancreas	No	Simvastatin 40 mg	Gemcitabine	114	6.6 vs 8.9 m, <i>p</i> =0.83
Lim 2015, BJC [85]	III	Metastatic CRC	Yes	Simvastatin 40 mg	XELIR/FOLFIRI	269	15.3 vs 19.2 m, <i>p</i> =0.83
Konings 2010, EJC [86]	II	Unresectable gastric	No	Pravastatin 40 mg	Epirubicin, Cisplatin, Cape	30	8 vs 6 m, <i>p</i> >0.05
Seckl 2017, JCO [87]	III	SCLC	No	Pravastatin 40 mg	Etoposide and Cis/Carbo	846	14.6 vs 14.6 m, HR 1.01, <i>p</i> =0.90
Alexandre 2017, BMJ Gut [88]	Feasibility	Resectable oesophageal	No	Simvastatin 40 mg	Surgery	32	HR 1.56, <i>p</i> =0.716*
Jouve 2019, J Hepatol [89]	III	Advanced liver	No	Pravastatin 40 mg	Sorafenib	323	10.7 vs 10.5, HR 1.00, <i>p</i> =0.975

*Feasibility study, not powered for overall survival analysis

combination therapy or sorafenib alone, which demonstrated no significant difference in OS between treatment arms [89]. The justification to proceed with a phase III multicentre trial in this context was based on more traditional evidence from pre-clinical and observational studies, one meta-analyses and an initial phase II study, with no contribution to the evidence base from more contemporary methods.

A number of other trials are currently underway; however, the use of more contemporary methods to support the go/no-go decision in proceeding with a clinical trial may help to reduce the likelihood of negative trials.

The Tolerability of Statin Therapy

The model for evaluating repurposed drugs should consider its toxicity and tolerability, particularly in the adjuvant setting, where significant or chronic toxicity may limit adherence. A well-documented adverse effect of statin therapy is muscle toxicity, including myopathy and rhabdomyolysis. Myopathy occurs in fewer than 1 in 10,000 individuals, although risk is considered related to both statin type and dose [90]. Persistent and asymptomatic increases in serum transaminases have been reported, although usually recover on discontinuation. There have however been rare post-marketing reports of hepatic failure. Generally, statins are considered well tolerated, and reasonably good 5-year compliance has been demonstrated in prior RCTs [38]. However, meta-analyses of individual patient data evaluating the safety of patients enrolled onto RCTs of statins in cardiovascular disease would provide a more comprehensive summary of the risk of adverse events. The CTT Collaboration is currently examining this data [91] and evaluation of safety would be an important part of any new phase III cancer trial.

A Potential Model for Evaluating Repurposed Drugs in Cancer Chemoprevention

Figure 1a demonstrates the conventional pathway of drug development. Following the discovery of a promising compound, supporting evidence from pre-clinical and observational data typically leads to clinical trials evaluating safety and efficacy. On average, the time between drug discovery and clinical trial is 9 years, with a huge cost involved, and success rate of less than 10% [92, 93]. Compared to the traditional drug discovery process, drug repurposing can considerably reduce the cost and time to bring a new treatment to patients, with many of the early steps in the drug development pathway already completed. The main justification for reusing licenced drugs for a new indication is that they have known mechanisms of actions and toxicity profiles [94]. However, despite these major advantages of drug repurposing, the issue

of efficacy remains the same [95], with overall success rate shown to be less than 6%, much like new oncological drug discovery [92, 96]. Therefore, careful consideration is required before embarking on a clinical trial [94]. The well-established model for drug discovery (Fig. 1a) is not designed for drug repurposing [97]. Major efforts need to be made to improve the rate of efficacy, perhaps considering a new adapted model for evaluating repurposed drugs. Figure 1b proposes a new evidence framework, particular to repurposed drugs, suggesting concurrent appraisal of already available data and the review of further evidence, prior to conducting a large RCT.

Conclusion

In conclusion, whilst most pre-clinical and observational evidence appears to support the use of statins in the prevention of cancer, results from the randomised vascular setting, pharmaco-epidemiological research using a target trial design, and evidence from MR have all been less convincing in most tumour types. There is little supportive evidence of the beneficial effects of statins as a treatment for cancer from phase III trials; however, most inferences have been limited to the non-curative setting. The challenge is, therefore, to weigh up the evidence from all sources as systematically and fairly as possible, as proposed by our model for evaluating repurposed drugs (Fig. 1a, b), to decide whether a trial in the adjuvant setting is justified on a tumour site-by-site basis. Further evaluation of the role of statins in the adjuvant setting may be justified, with breast cancer being one such candidate disease site to potentially investigate based on the evidence presented here. Future observational research emulating a hypothetical RCT, “a target trial”, in the adjuvant setting, and use of Mendelian randomization may help inform the decision to proceed to a potential phase III RCT of a repurposed drug.

Funding NJH receives a CRUK clinical trials fellowship grant from CRUK (C65320/A26413). RL reports grants from CRUK and NIHR, and honorarium from the Aspirin Foundation. LA is funded by the National Institute of Health Research (NIHR) as a clinical lecturer. RMM is supported in part by the National Institute for Health Research Bristol Biomedical Research Centre. RMM was supported by a Cancer Research UK (C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the UK National Institute for Health Research (NIHR) or the Department of Health and Social Care.

Declarations

Conflict of Interest Nalinie Joharatnam-Hogan is funded by a CRUK Clinical Trial Fellowship grant. Leo Alexandre is funded by the National Institute of Health Research (NIHR) as a clinical lecturer. James Yarmolinsky, Blossom Lake, Nigel Capps, Richard M. Martin, Alistair Ring, and Fay Cafferty declare no conflict of interest. Ruth Langley has

received research funding through grants from CRUK and NIHR, and has received honorarium from the Aspirin Foundation.

Ethics Approval and Consent to Participate This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
 - Of major importance
1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med.* 1996;335:1001–9.
 2. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet.* 2016;388:2532–61.
 3. Cholesterol Treatment Trialists C, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet.* 2015;385:1397–405.
 4. Kavalipati N, Shah J, Ramakrishnan A, Vasawala H. Pleiotropic effects of statins. *Indian journal of endocrinology and metabolism.* 2015;19:554–62.
 5. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *Lancet.* 2012;379:1591–601.
 6. Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. *BMC Cancer.* 2018;18:288.
 7. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. *Lancet Oncol.* 2012;13:518–27.
 8. Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, et al. ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. *Contemp Clin Trials.* 2016;51:56–64.
 9. Yarmolinsky J, Wade KH, Richmond RC, Langdon RJ, Bull CJ, Tilling KM, et al. Causal inference in cancer epidemiology: what is the role of Mendelian randomization? *Cancer epidemiology,*

- biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2018;27:995–1010.
10. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. *Pharmacol Rev*. 2012;64:102–46.
 11. Hindler K, Cleeland, C.s., Rivera, E., collard, C.D. The role of statins in cancer therapy. *Oncologist* 2006;11: 306–315.
 12. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. *Trends Pharmacol Sci*. 1998;19:26–37.
 13. Robinson RL, Suter W, Cox RH. Carcinogenicity and mutagenicity studies with fluvastatin, a new, entirely synthetic HMG-CoA reductase inhibitor. *Fundamental and Applied Toxicology*. 1993;23:9–20.
 14. MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, et al. Preclinical evaluation of lovastatin. *Am J Cardiol*. 1988;62:J16–27.
 15. Smith PF, Grossman SJ, Gerson RJ, Gordon LR, Deluca JG, Majka JA, et al. Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat. *Toxicol Pathol*. 1991;19:197–205.
 16. Narisawa T, Fukaura Y, Tanida N, Hasebe M, Ito M, Aizawa R. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1, 2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. *Tohoku J Exp Med*. 1996;180:131–8.
 17. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA*. 1996;275:55–60.
 18. Blais L, Desgagné A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the risk of cancer: a nested case-control study. *Arch Intern Med*. 2000;160:2363–8.
 19. Chen Y-A, Lin Y-J, Lin C-L, Lin H-J, Wu H-S, Hsu H-Y, et al. Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia. *Front Pharmacol*. 2018;9.
 20. Liu ZA, R., McGlynn, K., Anderson, L.A., Tsai, H., Zhu, B., Mbulaiteye, S.M., Gadalla, S.M., Koshiol, J. Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. *Gut*, *BMJ* 2018;0: 1–7.
 21. Akinwunmi B, Vitonis AF, Titus L, Terry KL, Cramer DW. Statin therapy and association with ovarian cancer risk in the New England Case Control (NEC) study. *Int J Cancer*. 2019;144:991–1000.
 22. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. *J Clin Oncol*. 2004;22:2388–94.
 23. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, et al. The association between statins and cancer incidence in a veterans population. *JNCI: Journal of the National Cancer Institute*. 2008;100:134–9.
 24. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolemia: a prospective registry study. *Eur Heart J*. 2008;29:2625–33.
 25. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, et al. Cancer risk among statin users: a population-based cohort study. *Int J Cancer*. 2005;114:643–7.
 26. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. *Eur J Cancer*. 2008;44:2122–32.
 27. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. *J Clin Oncol*. 2005;23:8606–12.
 28. Tan P, Wei S, Tang Z, Gao L, Zhang C, Nie P, et al. LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies. *Sci Rep*. 2016;6:24521.
 29. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. *Int J Cancer*. 2008;123:899–904.
 30. Lytras T, Nikolopoulos G, Bonovas S. Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. *World J Gastroenterol*. 2014;20:1858–70.
 31. Bansal D, Undela K, D'Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. *PLoS One*. 2012;7:e46691.
 32. Liu Y, Tang W, Wang J, Xie L, Li T, He Y, et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. *Cancer causes & control : CCC*. 2014;25:237–49.
 33. Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. *Ann Oncol*. 2013;24:1721–30.
 34. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. *Gut*. 2010;59:1572–85.
 35. Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of case-control studies. *Eur J Cancer Prev*. 2008;17:259–68.
 36. Jeong GH, Lee KH, Kim JY, Eisenhut M, Kronbichler A, van der Vliet HJ, et al. Effect of statin on cancer incidence: an umbrella systematic review and meta-analysis. *J Clin Med*. 2019;8:819.
 37. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet*. 2011;377:31–41.
 38. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. *Lancet* 2002;360: 7–22.
 39. Heart Protection Study Collaborative G. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. *Lancet*. 2011;378:2013–20.
 40. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. *Jama*. 2006;295:74–80.
 41. Kim MK, Myung SK, Tran BT, Park B. Statins and risk of cancer: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Indian J Cancer*. 2017;54:470–7.
 42. Cholesterol Treatment Trialists C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012;380: 581–590.
 43. Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy. *PLoS One* 2012;7: e29849.
 44. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670–81.
 45. Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, Bowman L, Braunwald E, Byington R, Cannon C, Clearfield M, Colhoun H, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019;393: 407–15. **This study, together with others performed by the Cholesterol Treatment Trialist Collaboration, pooled 186,854 individual patient data from multiple randomised vascular trials of statins, demonstrating no effect of statin therapy on cancer incidence or mortality.**
 46. Cholesterol Treatment Trialists C. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,

- 000 people in 27 randomised trials of statin therapy. *PLoS One* 2012;7: e29849.
47. Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). *Bmj*. 2018;363:k3532.
 48. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol*. 2015;44:827–36.
 49. Jankowski JAZ, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. *Lancet*. 2018;392:400–8.
 50. Soni PD, Hartman HE, Dess RT, Abugharib A, Allen SG, Feng FY, et al. Comparison of population-based observational studies with randomized trials in oncology. *J Clin Oncol*. 2019;37:1209–16.
 51. Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, et al. Effect estimates in randomized trials and observational studies: comparing apples with apples. *Am J Epidemiol*. 2019;188:1569–77.
 52. Hernan MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. *Epidemiology*. 2008;19:766–79.
 53. Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *Am J Epidemiol*. 2016;183:758–64.
 - 54.♦♦ Dickerman BA, García-Albéniz X, Logan RW, Denaxas S, Hernán MA. Avoidable flaws in observational analyses: an application to statins and cancer. *Nat Med* 2019;25: 1601–6. **This study used novel pharmacoepidemiological research to emulate a “target trial” of statins in cancer and analysed the electronic health records of 733,804 UK adults. They found little evidence to suggest that statin therapy influences cancer incidence after 10-year follow-up, which did not replicate the positive findings from observational study results—a study design that can be prone to bias.**
 55. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. *Epidemiology (Cambridge, Mass)*. 2017;28(1):30–42.
 56. Orho-Melander M, Hindy G, Borgquist S, Schulz CA, Manjer J, Melander O, et al. Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study. *Int J Epidemiol*. 2018;47:495–505.
 57. Bull CJ, Bonilla C, Holly JMP, Perks CM, Davies N, Haycock P, et al. Blood lipids and prostate cancer: a Mendelian randomization analysis. *Cancer Med*. 2016;5:1125–36.
 58. Nowak C, Arnlov J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk. *Nat Commun*. 2018;9: 3957.
 - 59.♦♦ Yamolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, Lewis SJ, Relton CL, Martin RM. Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian cancer. *JAMA* 2020;323: 646–55. **This is a study of Mendelian randomization as a method to evaluate the possible association of statins and epithelial ovarian cancer, using a genetic variant as a proxy for HMG-CoA reductase inhibition, which is thereby less prone to confounding than conventional observational studies. It demonstrated evidence of a lower risk of epithelial ovarian cancer in both the general population and in BRCA 1/2 mutation carriers, consistent with pre-clinical and epidemiological studies, perhaps warranting further investigation in this high-risk group.**
 60. Zheng J, Haberland, V., Baird, D., Walker, V., Haycocok, P., Gutteridge, A., Richardson T., Staley, J., Elsworth, B., Burgess, S., Sun, B. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases 2019.
 61. Paternoster L, Tilling K, Davey SG. Genetic epidemiology and Mendelian randomization for informing disease therapeutics: conceptual and methodological challenges. *PLoS Genet*. 2017;13(10): e1006944.
 62. Beckwitt CH, Clark AM, Ma B, Whaley D, Oltvai ZN, Wells A. Statins attenuate outgrowth of breast cancer metastases. *Br J Cancer*. 2018;119:1094–105.
 63. Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP. Statins and breast cancer prognosis: evidence and opportunities. *Lancet Oncol*. 2014;15:e461–8.
 64. Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after diagnosis of breast cancer and survival: a population-based cohort study. *Epidemiology (Cambridge, Mass)* 2015;26: 68–78.
 65. Cardwell CR, Mc Menamin U, Hughes CM, Murray LJ. Statin use and survival from lung cancer: a population-based cohort study. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2015;24:833–41.
 66. Voomeveld PW, Reimers MS, Bastiaannet E, Jacobs RJ, van Eijk R, Zanders MMJ, Herings RMC, van Herk-Sukel MPP, Kodach LL, van Wezel T, Kuppen PJK, Morreau H, et al. Statin use after diagnosis of colon cancer and patient survival. *Gastroenterology* 2017;153: 470–9.e4.
 67. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. *J Natl Cancer Inst*. 2011;103:1461–8.
 68. Cronin-Fenton D, Lash TL, Ahern TP, Damkier P, Christiansen P, Ejlersten B, et al. Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database. *Acta Oncol*. 2018;57:120–8.
 69. Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. *Int J Cancer*. 2016;139:1281–8.
 70. Mayeda ER, Glymour MM. The obesity paradox in survival after cancer diagnosis: tools for evaluation of potential bias. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2017;26(1):17–20.
 71. Mei Z, Liang M, Li L, Zhang Y, Wang Q, Yang W. Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. *Int J Cancer*. 2017;140:1068–81.
 72. He Y, Li X, Gasevic D, Brunt E, McLachlan F, Millenson M, Timofeeva M, Ioannidis JPA, Campbell H, Theodoratou E. Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials. *Ann Intern Med* 2018.
 73. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. *Cancer Investig*. 2011;29:585–93.
 74. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. *Breast Cancer Res Treat*. 2008;109:573–9.
 75. Borgquist S, Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Lang I, et al. Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study. *J Clin Oncol*. 2017;35:1179–88.
 76. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J Epidemiol*. 2003;158:915–20.

77. Emilsson L, García-Albéniz X, Logan RW, Caniglia EC, Kalager M, Hernán MA. Examining bias in studies of statin treatment and survival in patients with cancer. *JAMA Oncol*. 2018;4:63–70.
78. Davies JR, Field S, Randerson-Moor J, Harland M, Kumar R, Anic GM, et al. An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study. *Pigment Cell Melanoma Res*. 2014;27(2):234–43.
79. Bonilla C, Lewis SJ, Rowlands M-A, Gaunt TR, Davey Smith G, Gunnell D, et al. Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: genetic variants as instruments for circulating levels. *Int J Cancer*. 2016;139(7):1520–33.
80. Davies NM, Gaunt TR, Lewis SJ, et al. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. *Cancer Causes Control*. 2015;26(11):1603–16.
81. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. *Br J Cancer*. 2001;84:886–91.
82. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. *Breast Cancer Res Treat*. 2010;119:137–44.
83. Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, et al. Simvastatin plus capecitabine–cisplatin versus placebo plus capecitabine–cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. *Eur J Cancer*. 2014;50:2822–30.
84. Hong JY, Nam EM, Lee J, Park JO, Lee S-C, Song S-Y, et al. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. *Cancer Chemother Pharmacol*. 2014;73:125–30.
85. H Lim S, Kim TW, S Hong Y, Han SW, Lee K, J Kang H, Hwang I, Y Lee J, S Kim H, T Kim S, Lee J, O Park J, et al. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. vol. 113, 2015.
86. Konings IRHM, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FALM, Sleijfer S. The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. *Eur J Cancer*. 2010;46:3200–4.
87. Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, et al. Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung Cancer (LUNGSTAR). *J Clin Oncol*. 2017;35:1506–14.
88. Alexandre L, Clark AB, Walton S, Lewis MP, Kumar B, Cheong EC, et al. Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study. *BJS Open*. 2020;4:59–70.
89. Jouve JL, Lecomte T, Bouche O, Barbier E, Khemissa Akouz F, Riachi G, et al. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. *J Hepatol*. 2019;71:516–22.
90. Armitage J. The safety of statins in clinical practice. *Lancet*. 2007;370:1781–90.
91. Reith C, Blackwell L, Emberson J, Mihaylova B, Armitage J, Fulcher J, et al. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. *Am Heart J*. 2016;176:63–9.
92. Nowak-Sliwinska P, Scapozza L, Ruiz I, Altaba A. Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer. *Biochim Biophys Acta Rev Cancer*. 2019;1871(2):434–54.
93. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. *Nat Rev Drug Discov*. 2004;3(8):673–83.
94. Schein CH. Repurposing approved drugs on the pathway to novel therapies. *Med Res Rev*. 2020;40(2):586–605.
95. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? *Nat Rev Drug Discov*. 2004;3(8):711–5.
96. Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. *Drug Discov Today*. 2016;21(7):1189–95.
97. Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. *JAMA Intern Med*. 2017;177:1569–75.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.